RT Journal Article
T1 Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
A1 Ocaña, Alberto
A1 Chacon, Jose Ignacio
A1 Calvo, Lourdes
A1 Anton, Antonio
A1 Mansutti, Mauro
A1 Albanell, Joan
A1 Martinez, Maria Teresa
A1 Lahuerta, Ainhara
A1 Bisagni, Giancarlo
A1 Bermejo, Begoña
A1 Semiglazov, Vladimir
A1 Thill, Marc
A1 Chan, Arlene
A1 Morales, Serafin
A1 Herranz, Jesus
A1 Tusquets, Ignacio
A1 Chiesa, Massimo
A1 Caballero, Rosalía
A1 Valagussa, Pinuccia
A1 Bianchini, Giampaolo
A1 Alba, Emilio
A1 Gianni, Luca
K1 DNLR
K1 PCR
K1 Breast cancer
K1 Immunology
K1 Neoadjuvant chemotherapy
AB Derived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with clinical outcome in breast cancer (BC). We analyzed the association of dNLR with pathological complete response (pCR) in triple-negative BC (TNBC) patients receiving neoadjuvant chemotherapy (CT). This is a retrospective analysis of two randomized studies involving early stage/locally advanced TNBC patients receiving anthracycline/taxane-based CT+/-carboplatin (GEICAM/2006-03) or nab-paclitaxel/paclitaxel followed by anthracycline regimen (ETNA). dNLR was calculated as the ratio of neutrophils to the difference between total leukocytes and neutrophils in peripheral blood before CT (baseline) and at the end of treatment (EOT). Logistic regression analyses were used to explore dNLR association with pCR. In total, 308 TNBC patients were analyzed, 216 from ETNA and 92 from GEICAM/2006-03. Baseline median dNLR was 1.61 (interquartile range (IQR): 1.25-2.04) and at EOT 1.53 (IQR: 0.96-2.22). Baseline dNLR showed positive correlation with increased tumor size (p-value = 1e-04). High baseline dNLR, as continuous variable or using median cutoff, was associated with lower likelihood of pCR in univariate analysis. High EOT dNLR as continuous variable or using quartiles was also associated with lower pCR rate in uni- and multivariate analyses. High baseline and EOT dNLR correlates with lower benefit from neoadjuvant CT in TNBC.
PB Frontiers Research Foundation
SN 2234-943X
YR 2022
FD 2022-02-11
LK http://hdl.handle.net/10668/20678
UL http://hdl.handle.net/10668/20678
LA en
NO Ocaña A, Chacón JI, Calvo L, Antón A, Mansutti M, Albanell J, et al. Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Front Oncol. 2022 Feb 11;11:827625
DS RISalud
RD Apr 14, 2025